Mean platelet volume

Last updated
Mean platelet volume
Purposecan be used to make inferences about platelet production in bone marrow or platelet destruction problems

Mean platelet volume (MPV) is a machine-calculated measurement of the average size of platelets found in blood and is typically included in blood tests as part of the CBC. Since the average platelet size is larger when the body is producing increased numbers of platelets, the MPV test results can be used to make inferences about platelet production in bone marrow or platelet destruction problems. [1]

Contents

An increased mean platelet volume (MPV) increases the risk to suffer a heart disease [2]

MPV may be higher when there is destruction of platelets. This may be seen in immune thrombocytopenic purpura (ITP), myeloproliferative diseases and Bernard–Soulier syndrome. It may also be related to pre-eclampsia and recovery from transient hypoplasia. [3]

Abnormally low MPV values may correlate with thrombocytopenia when it is due to impaired production of megakaryocytes in the bone marrow, such as in aplastic anemia. A low MPV may indicate inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis. [4] A high MPV is also a bad prognostic marker in patients with sepsis or septic shock. [5] [6] In addition, low MPV may correlate with abnormally small platelet size, sometimes a symptom of a spectrum referred to as Wiskott–Aldrich syndrome (WAS), [7] caused by a genetic mutation of the WAS gene.

Sample for MPV testing is obtained in a Lavender-Top EDTA tube. A typical range of platelet volumes is 7.2 - 11.7 fL [8] (femtolitre), equivalent to spheres 2.65 to 2.9  μm in diameter.

Conditions associated with altered MPV

Decreased MPV

Increased MPV

Inherited thrombocytopenia with normal MPV

Related Research Articles

<span class="mw-page-title-main">Myelodysplastic syndrome</span> Diverse collection of blood-related cancers

A myelodysplastic syndrome (MDS) is one of a group of cancers in which immature blood cells in the bone marrow do not mature, and as a result, do not develop into healthy blood cells. Early on, no symptoms typically are seen. Later, symptoms may include fatigue, shortness of breath, bleeding disorders, anemia, or frequent infections. Some types may develop into acute myeloid leukemia.

<span class="mw-page-title-main">Platelet</span> Component of blood aiding in coagulation

Platelets or thrombocytes are a component of blood whose function is to react to bleeding from blood vessel injury by clumping, thereby initiating a blood clot. Platelets have no cell nucleus; they are fragments of cytoplasm derived from the megakaryocytes of the bone marrow or lung, which then enter the circulation. Platelets are found only in mammals, whereas in other vertebrates, thrombocytes circulate as intact mononuclear cells.

Aplastic anemia (AA) is a severe hematologic condition in which the body fails to make blood cells in sufficient numbers. Aplastic anemia is associated with cancer and various cancer syndromes. Blood cells are produced in the bone marrow by stem cells that reside there. Aplastic anemia causes a deficiency of all blood cell types: red blood cells, white blood cells, and platelets.

<span class="mw-page-title-main">Disseminated intravascular coagulation</span> Medical condition where blood clots block small blood vessels

Disseminated intravascular coagulation (DIC) is a condition in which blood clots form throughout the body, blocking small blood vessels. Symptoms may include chest pain, shortness of breath, leg pain, problems speaking, or problems moving parts of the body. As clotting factors and platelets are used up, bleeding may occur. This may include blood in the urine, blood in the stool, or bleeding into the skin. Complications may include organ failure.

<span class="mw-page-title-main">Thrombocytopenia</span> Abnormally low levels of platelets in the blood

In hematology, thrombocytopenia is a condition characterized by abnormally low levels of platelets in the blood. Low levels of platelets in turn may lead to prolonged or excessive bleeding. It is the most common coagulation disorder among intensive care patients and is seen in a fifth of medical patients and a third of surgical patients.

<span class="mw-page-title-main">Bleeding diathesis</span> Medical condition

In medicine (hematology), bleeding diathesis is an unusual susceptibility to bleed (hemorrhage) mostly due to hypocoagulability, in turn caused by a coagulopathy. Therefore, this may result in the reduction of platelets being produced and leads to excessive bleeding. Several types of coagulopathy are distinguished, ranging from mild to lethal. Coagulopathy can be caused by thinning of the skin, such that the skin is weakened and is bruised easily and frequently without any trauma or injury to the body. Also, coagulopathy can be contributed by impaired wound healing or impaired clot formation.

<span class="mw-page-title-main">Wiskott–Aldrich syndrome</span> Medical condition

Wiskott–Aldrich syndrome (WAS) is a rare X-linked recessive disease characterized by eczema, thrombocytopenia, immune deficiency, and bloody diarrhea. It is also sometimes called the eczema-thrombocytopenia-immunodeficiency syndrome in keeping with Aldrich's original description in 1954. The WAS-related disorders of X-linked thrombocytopenia (XLT) and X-linked congenital neutropenia (XLN) may present with similar but less severe symptoms and are caused by mutations of the same gene.

Primary myelofibrosis (PMF) is a rare bone marrow blood cancer. It is classified by the World Health Organization (WHO) as a type of myeloproliferative neoplasm, a group of cancers in which there is activation and growth of mutated cells in the bone marrow. This is most often associated with a somatic mutation in the JAK2, CALR, or MPL genes. In PMF, the bony aspects of bone marrow are remodeled in a process called osteosclerosis; in addition, fibroblast secrete collagen and reticulin proteins that are collectively referred to as (fibrosis). These two pathological processes compromise the normal function of bone marrow resulting in decreased production of blood cells such as erythrocytes, granulocytes and megakaryocytes, the latter cells responsible for the production of platelets.

Evans syndrome is an autoimmune disease in which an individual's immune system attacks their own red blood cells and platelets, the syndrome can include immune neutropenia. These immune cytopenias may occur simultaneously or sequentially.

Pancytopenia is a medical condition in which there is significant reduction in the number of almost all blood cells.

<span class="mw-page-title-main">Bernard–Soulier syndrome</span> Medical condition

Bernard–Soulier syndrome (BSS) is a rare autosomal recessive bleeding disorder that is caused by a deficiency of the glycoprotein Ib-IX-V complex (GPIb-IX-V), the receptor for von Willebrand factor. The incidence of BSS is estimated to be less than 1 case per million persons, based on cases reported from Europe, North America, and Japan. BSS is a giant platelet disorder, meaning that it is characterized by abnormally large platelets.

<span class="mw-page-title-main">GATA1</span> Protein-coding gene in humans

GATA-binding factor 1 or GATA-1 is the founding member of the GATA family of transcription factors. This protein is widely expressed throughout vertebrate species. In humans and mice, it is encoded by the GATA1 and Gata1 genes, respectively. These genes are located on the X chromosome in both species.

<span class="mw-page-title-main">Eltrombopag</span> Chemical compound

Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia and severe aplastic anemia. Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. It is a thrombopoietin receptor agonist. It is taken by mouth.

Hematologic diseases are disorders which primarily affect the blood and blood-forming organs. Hematologic diseases include rare genetic disorders, anemia, HIV, sickle cell disease and complications from chemotherapy or transfusions.

<span class="mw-page-title-main">Congenital amegakaryocytic thrombocytopenia</span> Medical condition

Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare autosomal recessive bone marrow failure syndrome characterized by severe thrombocytopenia, which can progress to aplastic anemia and leukemia. CAMT usually manifests as thrombocytopenia in the initial month of life or in the fetal phase. Typically CAMPT presents with petechiae, cerebral bleeds, recurrent rectal bleeding, or pulmonary hemorrhage.

Harris platelet syndrome, previously known as asymptomatic constitutional macrothrombocytopenia, is the most common inherited giant platelet disorder in the Indian subcontinent. It is characterized by a functional thrombocytopenia due to the presence of giant platelet cells.

<span class="mw-page-title-main">Giant platelet disorder</span> Medical condition

Giant platelet disorders, also known as macrothrombocytopenia, are rare disorders featuring abnormally large platelets, thrombocytopenia and a tendency to bleeding. Giant platelets cannot stick adequately to injured blood vessel walls, resulting in abnormal bleeding when injured. Giant platelet disorder occurs for inherited diseases like Bernard–Soulier syndrome, gray platelet syndrome and May–Hegglin anomaly.

<span class="mw-page-title-main">X-linked thrombocytopenia</span> Medical condition

X-linked thrombocytopenia, also referred to as XLT or thrombocytopenia 1, is an inherited clotting disorder that primarily affects males. It is a WAS-related disorder, meaning it is caused by a mutation in the Wiskott–Aldrich syndrome (WAS) gene, which is located on the short arm of the X chromosome. WAS-related disorders include Wiskott–Aldrich syndrome, XLT, and X-linked congenital neutropenia (XLN). Of the WAS-related disorders, X-linked thrombocytopenia is considered to be the milder phenotype. Between 1 and 10 per million males worldwide are affected with this disorder. Females may be affected with this disorder but this is very rare since females have two X chromosomes and are therefore typically carriers of the mutation.

Transient myeloproliferative disease (TMD) occurs in a significant percentage of individuals born with the congenital genetic disorder, Down syndrome. It may occur in individuals who are not diagnosed with the syndrome but have some hematological cells containing genetic abnormalities that are similar to those found in Down syndrome. TMD usually develops in utero, is diagnosed prenatally or within ~3 months of birth, and thereafter resolves rapidly and spontaneously. However, during the prenatal-to-postnatal period, the disease may cause irreparable damage to various organs and in ~20% of individuals death. Moreover, ~10% of individuals diagnosed with TMD develop acute megakaryoblastic leukemia at some time during the 5 years following its resolution. TMD is a life-threatening, precancerous condition in fetuses as well as infants in their first few months of life.

References

  1. "Complete Blood Count (CBC)". Testing.com.
  2. Slavka, Georg; Perkmann, Thomas; Haslacher, Helmuth; Greisenegger, Stefan; Marsik, Claudia; Wagner, Oswald F.; Endler, Georg (February 2012). "Mean Platelet Volume May Represent a Predictive Parameter for Overall Vascular Mortality and Ischemic Heart Disease". Arteriosclerosis, Thrombosis, and Vascular Biology. 31 (5): 1215–1218. doi: 10.1161/ATVBAHA.110.221788 . PMID   21330610. S2CID   85367.
  3. Lippi G, Filippozzi L, Salvagno GL, Montagnana M, Franchini M, Guidi GC, Targher G (September 2009). "Increased mean platelet volume in patients with acute coronary syndromes". Archives of Pathology & Laboratory Medicine. 133 (9): 1441–3. doi:10.5858/133.9.1441. PMID   19722752.
  4. Liu S, Ren J, Han G, Wang G, Gu G, Xia Q, Li J (October 2012). "Mean platelet volume: a controversial marker of disease activity in Crohn's disease". European Journal of Medical Research. 17 (1): 27. doi: 10.1186/2047-783x-17-27 . PMC   3519557 . PMID   23058104.
  5. Mangalesh S, Dudani S, Malik A (March 2021). "Platelet Indices and Their Kinetics Predict Mortality in Patients of Sepsis". Indian Journal of Hematology & Blood Transfusion. 37 (4): 600–608. doi:10.1007/s12288-021-01411-2. PMC   7988247 . PMID   33776267.
  6. Gao Y, Li Y, Yu X, Guo S, Ji X, Sun T, et al. (2014-08-13). Stover CM (ed.). "The impact of various platelet indices as prognostic markers of septic shock". PLOS ONE. 9 (8): e103761. Bibcode:2014PLoSO...9j3761G. doi: 10.1371/journal.pone.0103761 . PMC   4131909 . PMID   25118886.
  7. "Wiskott-Aldrich Syndrome". Immune Deficiency Foundation. Retrieved 2019-03-03.
  8. Demirin H, Ozhan H, Ucgun T, Celer A, Bulur S, Cil H, Gunes C, Yildirim HA (May 28, 2011). "Normal range of mean platelet volume in healthy subjects: Insight from a large epidemiologic study". PubMed National Library of Medicine. Retrieved 2024-05-25.{{cite web}}: CS1 maint: multiple names: authors list (link) CS1 maint: url-status (link)
  9. McClatchey KD (2002). Clinical Laboratory Medicine. Lippincott Williams & Wilkins. ISBN   9780683307511.
  10. "Paris-Trousseau syndrome". MrLabTest. Retrieved 2022-05-10.
  11. Geil GD (7 August 2020). Yaish HM (ed.). "Bernard-Soulier Syndrome Workup: Approach Considerations". emedicine.staging.medscape.com. Retrieved 2018-02-22.

Further reading